News & Updates

Show Multimedia Only

Family history of CRC ups risk of adenoma, neoplasia

17 Mar 2025 by

Individuals with a family history of colorectal cancer (CRC) are at greater risk of developing adenoma, nonadvanced adenoma (NAA), advanced adenoma (AA), and advanced neoplasia (AN), reveals a study.

Family history of CRC ups risk of adenoma, neoplasia

17 Mar 2025

$Upadacitinib for refractory CD safe, effective in real-world use$

Upadacitinib for refractory CD safe, effective in real-world use

13 Mar 2025

In a real-world cohort of patients with highly refractory Crohn’s disease (CD), upadacitinib treatment prompted clinical response in most and steroid-free clinical remission in half, while having an acceptable safety profile.

Upadacitinib for refractory CD safe, effective in real-world use

13 Mar 2025

NIPS regimen improves OS in gastric cancer with peritoneal metastasis

12 Mar 2025 by

Among patients with gastric cancer and peritoneal metastasis, treatment with neoadjuvant intraperitoneal–systemic (NIPS) regimen, which consists of intraperitoneal (IP) and intravenous (IV) paclitaxel plus S-1, significantly improved overall survival (OS) compared with IV paclitaxel plus S-1 only (PS regimen), according to the DRAGON-01 trial presented at ASCO GI 2025.

NIPS regimen improves OS in gastric cancer with peritoneal metastasis

12 Mar 2025

COVID-19 may leave lingering GI issues in children

10 Mar 2025 by

In children and adolescents who have contracted COVID-19, gastrointestinal (GI) tract symptoms may remain for up to 2 years, as reported in a large retrospective study.

COVID-19 may leave lingering GI issues in children

10 Mar 2025

Original New Drug Application Approvals by US FDA (1-15 February 2025)

10 Mar 2025

New drug applications approved by US FDA as of 1-15 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 February 2025)

10 Mar 2025

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

07 Mar 2025 by

The attainment of remission in EGPA is durable whether treated with benralizumab for 2 years or switched to benralizumab after 52 weeks of mepolizumab treatment, with additional merits observed among those who switched, as indicated in the OLE of MANDARA

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

07 Mar 2025

Leisure-time physical activity helps prevent hepatic steatosis

05 Mar 2025 by

Leisure-time physical activity (PA) offers protection against hepatic steatosis, with greater benefits seen among women and young people, suggests a study. Additionally, increasing leisure-time PA in men helps prevent liver fibrosis.

Leisure-time physical activity helps prevent hepatic steatosis

05 Mar 2025

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

05 Mar 2025 by

The combination of nivolumab and ipilimumab (NIVO + IPI) significantly improves overall survival (OS) and objective response rate (ORR) compared with lenvatinib or sorafenib (LEN/SOR) in the first-line setting for patients with unresectable hepatocellular carcinoma (uHCC), based on the CheckMate 9DW expanded analyses presented at ASCO GI 2025.

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

05 Mar 2025

Real-world data support FTD/TPI plus bevacizumab for mCRC

03 Mar 2025 by

A combination regimen comprising trifluridine/tipiracil (FTD/TPI) and bevacizumab demonstrates favourable efficacy and safety in individuals with metastatic colorectal cancer (mCRC) in the real-world BeTAS study presented at ASCO GI 2025.

Real-world data support FTD/TPI plus bevacizumab for mCRC

03 Mar 2025

JAK inhibitors tied to high remission rates in older adults with IBD

01 Mar 2025 by

Treatment with Janus kinase (JAK) inhibitors, particularly tofacitinib and upadacitinib, was associated with high rates of clinical, endoscopic, and histologic remission in older adults with moderate-to-severe inflammatory bowel disease (IBD), according to a study presented at CCC 2025.

JAK inhibitors tied to high remission rates in older adults with IBD

01 Mar 2025

News & Updates

Filter by Specialty:

Specialty:

Family history of CRC ups risk of adenoma, neoplasia

Family history of CRC ups risk of adenoma, neoplasia

Upadacitinib for refractory CD safe, effective in real-world use

Upadacitinib for refractory CD safe, effective in real-world use

NIPS regimen improves OS in gastric cancer with peritoneal metastasis

NIPS regimen improves OS in gastric cancer with peritoneal metastasis

COVID-19 may leave lingering GI issues in children

COVID-19 may leave lingering GI issues in children

Original New Drug Application Approvals by US FDA (1-15 February 2025)

Original New Drug Application Approvals by US FDA (1-15 February 2025)

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

Leisure-time physical activity helps prevent hepatic steatosis

Leisure-time physical activity helps prevent hepatic steatosis

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

Real-world data support FTD/TPI plus bevacizumab for mCRC

Real-world data support FTD/TPI plus bevacizumab for mCRC

JAK inhibitors tied to high remission rates in older adults with IBD

JAK inhibitors tied to high remission rates in older adults with IBD